CZO Stock Overview
Ceapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$0.67|
|52 Week High||CA$0.82|
|52 Week Low||CA$0.40|
|1 Month Change||-15.19%|
|3 Month Change||13.56%|
|1 Year Change||3.08%|
|3 Year Change||71.80%|
|5 Year Change||-4.29%|
|Change since IPO||-62.78%|
Recent News & Updates
Ceapro's (CVE:CZO) Returns Have Hit A Wall
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...
|CZO||CA Chemicals||CA Market|
Return vs Industry: CZO underperformed the Canadian Chemicals industry which returned 26% over the past year.
Return vs Market: CZO exceeded the Canadian Market which returned -6.2% over the past year.
|CZO Average Weekly Movement||8.2%|
|Chemicals Industry Average Movement||11.3%|
|Market Average Movement||9.9%|
|10% most volatile stocks in CA Market||18.1%|
|10% least volatile stocks in CA Market||3.8%|
Stable Share Price: CZO is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: CZO's weekly volatility (8%) has been stable over the past year.
About the Company
Ceapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. It operates in two segments, Active Ingredient Product Technology Industry and Cosmeceutical Industry. The Active Ingredient Product Technology Industry segment develops proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries.
Ceapro Fundamentals Summary
|CZO fundamental statistics|
Is CZO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CZO income statement (TTM)|
|Cost of Revenue||CA$7.37m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.068|
|Net Profit Margin||26.88%|
How did CZO perform over the long term?See historical performance and comparison
Is CZO undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CZO?
Other financial metrics that can be useful for relative valuation.
|What is CZO's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does CZO's PE Ratio compare to its peers?
|CZO PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
NEO Neo Performance Materials
WRX Western Resources
MJS Majestic Gold
SGI Superior Gold
Price-To-Earnings vs Peers: CZO is good value based on its Price-To-Earnings Ratio (9.9x) compared to the peer average (12.9x).
Price to Earnings Ratio vs Industry
How does CZO's PE Ratio compare vs other companies in the North American Chemicals Industry?
Price-To-Earnings vs Industry: CZO is good value based on its Price-To-Earnings Ratio (9.9x) compared to the North American Chemicals industry average (10.8x)
Price to Earnings Ratio vs Fair Ratio
What is CZO's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||9.9x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate CZO's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of CZO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CZO (CA$0.67) is trading below our estimate of fair value (CA$1.92)
Significantly Below Fair Value: CZO is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Ceapro forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Materials industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Ceapro has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
How has Ceapro performed over the past 5 years?
Past Performance Score5/6
Past Performance Score 5/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CZO has high quality earnings.
Growing Profit Margin: CZO's current net profit margins (26.9%) are higher than last year (5.5%).
Past Earnings Growth Analysis
Earnings Trend: CZO's earnings have grown significantly by 56% per year over the past 5 years.
Accelerating Growth: CZO's earnings growth over the past year (528.8%) exceeds its 5-year average (56% per year).
Earnings vs Industry: CZO earnings growth over the past year (528.8%) exceeded the Chemicals industry 278.8%.
Return on Equity
High ROE: CZO's Return on Equity (17.2%) is considered low.
Discover strong past performing companies
How is Ceapro's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: CZO's short term assets (CA$17.1M) exceed its short term liabilities (CA$917.1K).
Long Term Liabilities: CZO's short term assets (CA$17.1M) exceed its long term liabilities (CA$2.9M).
Debt to Equity History and Analysis
Debt Level: CZO is debt free.
Reducing Debt: CZO has no debt compared to 5 years ago when its debt to equity ratio was 8.8%.
Debt Coverage: CZO has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CZO has no debt, therefore coverage of interest payments is not a concern.
Discover healthy companies
What is Ceapro current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Ceapro Dividend Yield vs Market|
|Market Bottom 25% (CA)||2.0%|
|Market Top 25% (CA)||6.1%|
|Industry Average (Chemicals)||2.4%|
|Analyst forecast in 3 Years (Ceapro)||n/a|
Notable Dividend: Unable to evaluate CZO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CZO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CZO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CZO's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CZO has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Gilles Gagnon (68 yo)
Mr. Gilles R. Gagnon, M.Sc., MBA, ICD D, serves as Director at Aeterna Zentaris Inc. since January 1, 2020. He serves as the President of Spectrum Pharma Canada Inc. (Spectrum Canada).Mr. Gagnon has been...
CEO Compensation Analysis
|Gilles Gagnon's Compensation vs Ceapro Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||CA$560k||CA$480k|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||CA$507k||CA$480k|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||CA$518k||CA$480k|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||CA$555k||CA$480k|
|Sep 30 2018||n/a||n/a|
|Jun 30 2018||n/a||n/a|
|Mar 31 2018||n/a||n/a|
|Dec 31 2017||CA$1m||CA$480k|
|Sep 30 2017||n/a||n/a|
|Jun 30 2017||n/a||n/a|
|Mar 31 2017||n/a||n/a|
|Dec 31 2016||CA$402k||CA$252k|
|Sep 30 2016||n/a||n/a|
|Jun 30 2016||n/a||n/a|
|Mar 31 2016||n/a||n/a|
|Dec 31 2015||CA$377k||CA$252k|
Compensation vs Market: Gilles's total compensation ($USD407.88K) is above average for companies of similar size in the Canadian market ($USD176.56K).
Compensation vs Earnings: Gilles's compensation has been consistent with company performance over the past year.
Experienced Management: CZO's management team is seasoned and experienced (7.3 years average tenure).
Experienced Board: CZO's board of directors are considered experienced (7.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Ceapro Inc.'s employee growth, exchange listings and data sources
- Name: Ceapro Inc.
- Ticker: CZO
- Exchange: TSXV
- Founded: 1997
- Industry: Specialty Chemicals
- Sector: Materials
- Implied Market Cap: CA$52.406m
- Shares outstanding: 78.22m
- Website: https://www.ceapro.com
- Ceapro Inc.
- 7824 – 51 Avenue NW
- T6E 6W2
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CZO||TSXV (TSX Venture Exchange)||Yes||Class A Voting Common Shares||CA||CAD||Sep 1988|
|CRPO.F||OTCPK (Pink Sheets LLC)||Yes||Class A Voting Common Shares||US||USD||Sep 1988|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/30 00:00|
|End of Day Share Price||2022/09/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.